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LOW-DOSE TACROLIMUS IN THE TREATMENT OF SEVERE CHRONIC 
IDIOPATHIC URTICARIA
 Tacrolimus (FK 506; Prograf, Killorgin, Ire-
land), a macrolide lactone, is a potent inhibitor of 
histamine release from basophils activated by an-
tigen and anti-IgE as well as an inhibitor of hista-
mine release and de novo synthesized inflamma-
tory mediators (sulfidopeptide leukotriene C4 and 
prostaglandin D2) from mast cells.
 Aharon Kessel, Ellen Bamberger, and Elias 
Toubi (2004) decided to investigate the effect of 
tacrolimus on clinical features in 19 patients with 
severe unremitting chronic idiopathic urticaria 
(CIU) lasting for more than 12 months. The outpa-
tient study group was treated daily with tacrolimus, 
initially at a dose of 0.05 mg/kg to 0.07 mg/kg ad-
ministered orally twice a day for 4 weeks, followed 
by 6 weeks of 0.025 mg/kg/day to 0.035 mg/kg/
day. Subsequently, the drug was continued for 
an additional 2 weeks at a dose of 1 mg per day 
and then discontinued (total treatment period of 
12 weeks). By the end of treatment, improvement 
was noted in 9 of 12 responders, five patients were 
nonresponders. Ten of 12 responders were fol-
lowed for an additional 3 months after tacrolimus 
discontinuation. These first clinical data suggest 
that tacrolimus may be a reasonable treatment for 
severe CIU. To establish tacrolimus as an alterna-
tive treatment of CIU unresponsive cyclosporine, 
the optimal dose and duration of therapy for CIU 
needs to be investigated in double-blind, placebo 
controlled studies.
(From: Kessel A, Bamberger E, Toubi E. Tacroli-
mus in the treatment of severe chronic idiopathic 
urticaria: An open-label prospective study. J Am 
Acad Dermatol 2005;52:145-8).
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